XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 501,195 $ 647,169
Short-term investments 807,273 819,905
Trade receivables, net 214,784 282,650
Inventory 33,299 27,493
Prepaid expenses and other current assets 62,211 57,530
Total current assets 1,618,762 1,834,747
Long-term investments 756,731 371,112
Property and equipment, net 110,624 104,031
Deferred tax assets, net 231,110 111,663
Goodwill 63,684 63,684
Right-of-use assets and other 290,578 131,002
Total assets 3,071,489 2,616,239
Current liabilities:    
Accounts payable 32,667 24,258
Accrued compensation and benefits 77,158 61,969
Accrued clinical trial liabilities 65,072 77,544
Rebates and fees due to customers 50,350 33,700
Accrued collaboration liabilities 20,188 86,753
Other current liabilities 78,924 53,366
Total current liabilities 324,359 337,590
Long-term portion of deferred revenue 6,582 8,739
Long-term portion of operating lease liabilities 190,170 51,272
Other long-term liabilities 61,951 8,023
Total liabilities 583,062 405,624
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 323,951 and 318,842 at December 31, 2022 and 2021, respectively 324 319
Additional paid-in capital 2,536,849 2,427,561
Accumulated other comprehensive loss (14,521) (758)
Accumulated deficit (34,225) (216,507)
Total stockholders’ equity 2,488,427 2,210,615
Total liabilities and stockholders’ equity $ 3,071,489 $ 2,616,239